Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic.
Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the α4β2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction. Achieve’s focus is to address the global smoking health epidemic by making cytisinicline widely available.
Cytisinicline demonstrated quit rates at least as effective as varenicline yet with significantly fewer side effects in a 679-subject Phase 3 study led by Dr. Natalie Walker, Associate Professor at the University of Auckland.
Chantix® is a registered trademark of Pfizer Inc.
ORCA-1 Program Infographic. Click image to enlarge.
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial. 3.0 mg, 3 times daily selected as dose for future clinical development.
Smoking is a global public health epidemic responsible for the loss of over 7 million lives annually.
Cytisinicline
Cytisinicline is a plant-based smoking cessation treatment currently approved in Central and Eastern Europe.
Clinical Trials
ORCA: Ongoing Research of Cytisinicline for Addiction.
Investors
Achieve is a specialty pharmaceutical company focused global development of cytisinicline for smoking cessation.
Smoking is the #1 cause of preventable deaths worldwide.
According to the Centers for Disease Control and Prevention (CDC), 70% of current smokers expressed desire to quit, 55% attempted to quit, only 7% succeeded in quitting in the past year.